Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Boehringer Ingelheim and Lilly highlight cardiovascular benefits of Jardiance

Boehringer Ingelheim and Lilly highlight cardiovascular benefits of Jardiance

18th September 2015

Boehringer Ingelheim and Lilly have announced clinical trial data that demonstrates the cardiovascular health benefits associated with their diabetes drug Jardiance.

Findings from the EMPA-REG OUTCOME trial have indicated that Jardiance significantly reduced the risk of cardiovascular death, non-fatal heart attack or stroke by 14 percent when added to standard of care, in patients with type 2 diabetes and a high risk of cardiovascular events.

In addition, treatment with Jardiance resulted in the risk of all-cause mortality dropping by 32 percent and the rate of hospitalisation for heart failure falling by 35 percent.

This makes the drug the only diabetes medication to show a significant reduction in both cardiovascular risk and cardiovascular death in a dedicated outcome trial.

Dr Bernard Zinman, director, a professor of medicine at the University of Toronto in Canada, said: "Addressing the burden of cardiovascular events, including death, is at the core of diabetes care, and until now no single diabetes medication has been associated with a reduction in mortality."

This comes after Boehringer Ingelheim and Lilly recently reported clinical data showing that their biosimilar diabetes product Abasaglar can offer comparable safety and efficacy to the branded therapy Lantus.ADNFCR-8000103-ID-801800801-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.